Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting scheduled for December 31, 2025, to consider the approval of the Sinopharm Distribution Framework Agreement (2025 Renewal). This agreement, if approved, will facilitate continued collaboration with Sinopharm Group Co. Ltd., potentially enhancing the company’s distribution capabilities and market reach in the pharmaceutical sector.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of high-quality and affordable biologic medicines. The company operates in the biopharmaceutical industry, providing innovative therapeutic solutions primarily in the fields of oncology, autoimmune diseases, and ophthalmology.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.